Etodolac: the chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid.
L G Humber
Medicinal research reviews, 7(1), 1-28 (1987-01-01)
D R Brocks et al.
Clinical pharmacokinetics, 26(4), 259-274 (1994-04-01)
Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. Currently, the drug is available in several countries for the treatment of arthritis and the alleviation of pain. Etodolac possesses several unique disposition features mainly due...
Tetsuji Takayama et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 17(11), 3803-3811 (2011-03-10)
On the basis of the results of our preliminary trial suggesting that aberrant crypt foci (ACF) could be eradicated by short-term administration of sulindac, in the present study, we explored the feasibility of using ACF as surrogate markers for chemoprevention...
Z Adhim et al.
British journal of cancer, 105(3), 393-402 (2011-07-14)
Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of...
Soad S Abd el-Hay et al.
Journal of fluorescence, 22(1), 247-252 (2011-08-20)
A simple, selective and sensitive luminescence method has been developed for the assay of etodolac (I), moxepril HCl (II) and fexofenadine HCl (III) in bulk drug and pharmaceutical formulations. The method is based on the luminescence sensitization of europium (Eu(3+))...